Sagimet Biosciences Inc. (SGMT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. George W. Kemble Ph.D. | Executive Chairman of the Board | 484k | -- | 1962 |
| Mr. David A. Happel | CEO, President & Director | 836.18k | -- | 1962 |
| Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. | Chief Medical Officer | 649.33k | -- | 1963 |
| Mr. Urs Greber Ph.D. | Co-Founder | -- | -- | -- |
| Dr. Lucas Pelkmans Ph.D. | Co-Founder | -- | -- | -- |
| Mr. Thierry Chauche | CFO & Principal Accounting Officer | -- | -- | 1976 |
| Ms. Elizabeth Rozek Esq., J.D. | General Counsel & Chief Compliance Officer | -- | -- | 1972 |
| Dr. Marie O'Farrell Ph.D. | Senior Vice President of Research & Development | -- | -- | -- |
Sagimet Biosciences Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 8
Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
August 22, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission